A Phase 3 interventional study of Sublingual film containing Dexmedetomidine (BXCL501) and Placebo Film in Agitation Associated With Bipolar Disorder, Agitation,Psychomotor and Bipolar Disorder, sponsored by BioXcel Therapeutics Inc. Completed at 15 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by BioXcel Therapeutics Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing dexmedetomidine in Psychomotor Agitation — 5 open to participants now, 5 under way, 2 of them phase 3. Dexmedetomidine · Psychomotor Agitation.
Among the 32 studies testing dexmedetomidine in Psychomotor Agitation, this one is the 2nd largest by enrollment, is one of 4 that started in 2020, is one of 7 in phase 3, and was the 18th registered.
231 studies on the registry are indexed under Psychomotor Agitation; 28 are open to participants now.
Browse Psychomotor Agitation studies →5 of the 32 studies testing dexmedetomidine in Psychomotor Agitation are open now, in 3 countries. Recruiting first, the newest first:
Lone Baandrup · Sites in Denmark
Ages 18–64
Temple University · Sites in United States
Ages 18–55
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
Benha University
Ages 18+
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Ages 18+
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 20 Psychomotor Agitation studies recruiting now, 8 (40%) set no upper age limit and 7 (35%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 10 · Phase 4 11
First in 2005; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 380 is above the median of 100 across 188 interventional studies indexed under Psychomotor Agitation.
Median enrollment 73 across the 32 interventional studies. Of the 21 that completed or were terminated, 12 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 32 have an industry lead sponsor. The 10 most frequent:
BioXcel Therapeutics Inc is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 9 (75%) have results posted.
11 studies in Psychomotor Agitation by BioXcel Therapeutics Inc: none open now, none under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 11 studies in Psychomotor Agitation by BioXcel Therapeutics Inc, this one is the 2nd largest by enrollment, is one of 2 that started in 2020, is one of 5 in phase 3, and was the 4th registered.
BioXcel Therapeutics Inc’s Psychomotor Agitation studies by the year they started, since 2019.
None of the studies under way reaches primary completion within a year.
Among the 32 studies testing dexmedetomidine in Psychomotor Agitation, from their registry updates:
Among BioXcel Therapeutics Inc’s 11 in Psychomotor Agitation:
This tab as a report to print or save as PDF → With an account.
This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in bipolar disorder. The BXCL501-302 study is designed to characterize the efficacy, safety and tolerability of BXCL501 (sublingual film formulation of DEX, HCl) in agitation associated with bipolar disorder.
The study will enroll approximately 375 subjects randomized 1:1:1 to dose regimens of 180µg, 120µg BXCL501, or placebo stratified by age \< 65 and age ≥ 65. Male and female adults with acute agitation associated with bipolar disorder will be enrolled. Eligible subjects (acutely agitated subjects with bipolar disorder, generally hypomanic, manic or mixed episodes) may be identified in outpatient clinics, mental health, psychiatric or medical emergency services including medical/psychiatric observation units, or as newly admitted to a hospital setting for acute agitation or already in hospital for chronic underlying conditions. Subjects will be domiciled in a clinical research setting or hospitalized to remain under medical supervision while undergoing screening procedures to assess eligibility. Efficacy and safety assessments will be conducted periodically before and after dosing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sublingual film containing 120 Micrograms Dexmedetomidine
Drug: Sublingual film containing Dexmedetomidine (BXCL501)
Sublingual film containing 180 Micrograms Dexmedetomidine
Drug: Sublingual film containing Dexmedetomidine (BXCL501)
Sublingual placebo film
Drug: Placebo Film
Sublingual film containing Dexmedetomidine (BXCL501)
Also known as: Dexmedetomidine
Placebo Film for BXCL501
Also known as: Placebo
Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score
The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).
Time frame: Baseline and 120 minutes
Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score Over Time
Effect on agitation onset was measured by change from baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) total score. The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items -poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).
Time frame: Baseline and 20, 30, 45, 60, 90, 120 minutes post-dose
| Milestone | 180 Micrograms | 120 Micrograms | Placebo |
|---|---|---|---|
| Started | 127 | 127 | 126 |
| Completed | 123 | 119 | 120 |
| Not completed | 4 | 8 | 6 |
| Withdrew: Withdrawal by subject | 2 | 3 | 6 |
| Withdrew: Lost to follow-up | 1 | 3 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Randomized in error - di dnot receive treatment | 1 | 1 | 0 |
The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).
| score on a scale | 180 Micrograms | 120 Micrograms | Placebo |
|---|---|---|---|
| Baseline | 18.0 ± 2.99 | 18.0 ± 2.73 | 17.9 ± 2.94 |
| Change from Baseline at 120 Minutes | -10.4 ± 4.45 | -9.0 ± 5.26 | -4.9 ± 4.67 |
Effect on agitation onset was measured by change from baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) total score. The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items -poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).
| score on a scale | 180 Micrograms | 120 Micrograms | Placebo |
|---|---|---|---|
| Baseline | 18 ± 2.99 | 18 ± 2.73 | 17.9 ± 2.94 |
| Change from Baseline at 20 minutes | -3.1 ± 4.45 | -2.9 ± 3.83 | -1.9 ± 3 |
| Change from Baseline at 30 minutes | -4.6 ± 5.08 | -4.3 ± 4.86 | -2.8 ± 3.85 |
| Change from Baseline at 45 minutes | -6.7 ± 5.12 | -6.3 ± 5.3 | -3.6 ± 4.14 |
| Change from Baseline at 60 minutes | -8.4 ± 5.17 | -7.5 ± 5.19 | -4.4 ± 4.53 |
| Change from Baseline at 90 minutes | -9.7 ± 4.90 | -8.6 ± 5.28 | -4.7 ± 4.52 |
| Change from Baseline at 120 minutes | -10.4 ± 4.45 | -9.0 ± 5.26 | -4.9 ± 4.67 |
Collected over 30 days. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 180 Micrograms | 0/126 (0%) | 0/126 (0%) | 45/126 (35.7%) |
| 120 Micrograms | 0/126 (0%) | 1/126 (0.8%) | 44/126 (34.9%) |
| Placebo | 0/126 (0%) | 0/126 (0%) | 19/126 (15.1%) |
| Event | 180 Micrograms | 120 Micrograms | Placebo |
|---|---|---|---|
| AgitationNervous system disorders | 0/126 | 1/126 | 0/126 |
| Event | 180 Micrograms | 120 Micrograms | Placebo |
|---|---|---|---|
| SomnolenceNervous system disorders | 27/126 | 26/126 | 6/126 |
| Dry mouthGastrointestinal disorders | 6/126 | 9/126 | 1/126 |
| HypotensionVascular disorders | 8/126 | 6/126 | 0/126 |
| DizzinessNervous system disorders | 7/126 | 7/126 | 1/126 |
| HeadacheNervous system disorders | 2/126 | 6/126 | 6/126 |
| Orthostatic hypotensionVascular disorders | 6/126 | 5/126 | 1/126 |
| NauseaGastrointestinal disorders | 5/126 | 3/126 | 3/126 |
| Hypoesthesia oralGastrointestinal disorders | 5/126 | 2/126 | 1/126 |
Safety population (all participants who received study drug)
| Age, Continuous(years) | 180 Micrograms | 120 Micrograms | Placebo | Total |
|---|---|---|---|---|
| Mean | 45.9 ± 11.3 | 46.1 ± 11.5 | 44.8 ± 12.1 | 45.6 ± 11.6 |
| Sex: Female, Male(Participants) | 180 Micrograms | 120 Micrograms | Placebo | Total |
|---|---|---|---|---|
| Female | 67 | 67 | 73 | 207 |
| Male | 59 | 59 | 53 | 171 |
| Ethnicity (NIH/OMB)(Participants) | 180 Micrograms | 120 Micrograms | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 15 | 12 | 11 | 38 |
| Not Hispanic or Latino | 111 | 114 | 115 | 340 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 180 Micrograms | 120 Micrograms | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 72 | 68 | 72 | 212 |
| White | 49 | 56 | 50 | 155 |
| More than one race | 3 | 1 | 1 | 5 |
| Unknown or Not Reported | 1 | 1 | 1 | 3 |
| Positive and Negative Syndrome Scale-Excited Component (PEC)(units on a scale) | 180 Micrograms | 120 Micrograms | Placebo | Total |
|---|---|---|---|---|
| Mean | 18.0 ± 3.0 | 18.0 ± 2.7 | 17.9 ± 2.9 | 18.0 ± 2.9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2020 to primary completion in May 2020, 2 months.
Results were first posted in Sep 2023, 3 years 3 months after primary completion.
Of 23 phase 3 interventional studies under Psychomotor Agitation, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 47. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
BioXcel Therapeutics Inc